Table 3

Mean volumes of care and total direct costs in euros per patient per period in the treat-to-target (T2T) and usual care (UC) groups after two and three years of follow-up
0-2 year
T2T (n=261) UC (n=213) UC from 2006 (n=69)
Volume Costs Volume Costs Difference in costs Volume Costs Difference in costs
Consultations rheumatologist 10.4 ± 3.0 696 ± 199 10.3 ± 2.9 689 ± 195 7 10.2 ± 3.6 683 ± 239 13
Consultations nurse 8.8 ± 3.0 588 ± 200 7.8 ± 1.9† 522 ± 127† 66 6.6 ± 2.0† 438 ± 134† 150
Telephonic consultations 1.3 ± 1.8 34 ± 46 0.6 ± 1.4† 16 ± 36† 18 1.1 ± 1.9 29 ± 48 5
Hospital admissions 0.4 ± 2.7 178 ± 1,208 1.1 ± 4.2† 521 ± 1,901† -343 0.3 ± 1.6 158 ± 714 20
Medication
 DMARDs/other 174 ± 165 249 ± 340 -75 166 ± 119 8
 Anti-TNF 3,121 ± 7,162 1,730 ± 4,905† 1,391 1,877 ± 5,086 1244
Total 4,791 ± 7,436 3,727 ± 5,773 1,064 (1,026 to 1,121)‡ 3,351 ± 5,179† 1440 (1,387 to 1479)‡
0-3 year
T2T (n=127) UC (n=180) UC from 2006 (n=45)
Volume Costs Volume Costs Difference in costs Volume Costs Difference in costs
Consultations rheumatologist 13.7 ± 3.3 917 ± 220 13.6 ± 3.3 909 ± 224 8 12.5 ± 3.8 838 ± 253† 79
Consultations nurse 12.1 ± 3.6 809 ± 244 8.9 ± 1.7† 596 ± 117† 213 8.4 ± 2.2† 565 ± 145† 244
Telephonic consultations 1.9 ± 2.1 49 ± 54 0.8 ± 1.7† 21 ± 45† 28 1.7 ± 2.5 43 ± 64 6
Hospital admissions 0.5 ± 3.2 215 ± 1,441 1.6 ± 5.0† 748 ± 2,263† -533 0.8 ± 2.7 364 ± 1,217 -149
Medication
 DMARDs/other 260 ± 335 423 ± 612† -163 259 ± 174 1
 Anti-TNF 4,160 ± 10,685 4,175 ± 10,070 -15 5,488 ± 11,528 -1,328
Total 6,410 ± 10,845 6,872 ± 11,033 -462 (-513 to -350)‡ 7,558 ± 11,649 -1,148 (-1241 to -1075)‡

Volumes are the mean ± standard deviation (SD).

Anti-TNF, anti-tumour necrosis factor; CI, confidence interval; DMARDs, disease-modifying antirheumatic drugs.

† P < 0.05 for differences between groups (T2T versus UC). ‡ 95% confidence interval bootstrapped.

Vermeer et al.

Vermeer et al. BMC Musculoskeletal Disorders 2013 14:350   doi:10.1186/1471-2474-14-350

Open Data